Start-up failures – How can you plan for a successful market launch?

In a recent study funded by the Dutch government it was found that roughly 91% of start-ups fail! What are the reasons for that and more important how could you plan to be successful? MArS in cooperation with the Dutch consultancy Seijgraaf will present and discuss findings and solutions for a successful market access of health care start-ups. The webinar will include the following topics: • What are the major issues health care start-ups have when preparing to enter the launch? • What are must-haves in terms of market access and reimbursement for new products in the health care system? • How can a health care start-up be successful?

Webinar: Covid-19 in Europe – Germany ahead of others, but when will the second wave come and how will this potentially look like?

Germany has been seen at the forefront of the Covid-19 control and outcomes. The situation until end May is very promising with a reproduction number below one and new infections below 800 per day. Few hotspots have been identified and lock-down measures have been relaxed to a maximum. However, a core question remains: Not if, but when will a second wave of Covid-19 come and how will this potentially look like.

The MArS Covid-19 task force will present to you some realistic simulation scenarios based on epidemiological evidence.

Register now

New Webinar on Covid-19 and digitalization on May 28 2020

The covid-19 outbreak has had a significant impact on daily life of populations and health care systems. Due to physical distancing as a core policy, digitalization is a main opportunity also in health care. At the same time the new law for digitalization in health care (DiGA) was made effective In Germany.

The MArS Covid-19 task force will show you in this webinar:

  • How digitalization has changed the health care system
  • The different pathways for digitalization solutions to the German market

Register now: Webinars

Video available – MArS webinar – Covid-19 cost on Germany

On Thursday, April 23 2020, MArS offered the webinar “How many billion of Euros does the fight against the Covid-19-virus cost the healthcare system? A health economic modelling analysis for Germany”.

The presentation as a video is now available:

MArS has extensive experience in health economic modelling an support you in your endeavors.

Enjoy the video and stay healthy!

MArS webinar slides on cost of Covid-19 available

On Thursday, April 23 2020, MArS offered the webinar “How many billion of Euros does the fight against the Covid-19-virus cost the healthcare system? A health economic modelling analysis for Germany”.

The presented slides are now available on our website MArS – Stefan Walzer – Webinar – Covid-19 impact health economics Germany

MArS has extensive experience in health economic modelling an support you in your endeavors.

Stay healthy!

MArS-Webinar invitation: How many billion of Euros does the fight against the Covid-19-virus cost the healthcare system? A health economic modelling analysis for Germany.

The covid-19 outbreak has had a significant impact on daily life of populations and also a significant budget impact for health care systems. There are various statistical simulation tools available in the context of Covid-19 developed by different institutions. The CovidSIM is a simulator developed by academic experts on behalf of the ministry of social welfare (and health) of Baden-Wuerttemberg (Germany).

The MArS Covid-19 task force will show you in this webinar:

• How well this simulator can predict the outbreak and situation in Germany.

• How much the health care utilization cost have been so far for the German health care system.

• In which way you might leverage this simulation tool.

Register now – seats are limited: https://zoom.us/webinar/register/4915870254563/WN_q4mgDCXVRAiD_ZrYUgsSKQ

 

Covid-19 crisis makes KOLs availability difficult – MArS has the solution

Given the covid-19 crisis, most clinical KOLs are no more able to attend any physical meetings or even phone calls due to the heavy work load in some areas of the D-A-CH countries!
MArS is working since years in a step-wise approach for such situations, when KOLs might be difficult to be approached:
  • Physical Advisory Board Meeting
  • Virtual Advisory Board Meeting
  • Virtual Delphi Panel

Please contact us directly and get your tailor-made solution to stay in contact with your KOLs: stefan.walzer@marketaccess-pricingstrategy.de

G-BA prepared their decision-making capacity given the COVID-19 outbreak

The G-BA has decided today that the COVID-19 outbreak and the related public restrictions are special circumstances in their internal regulations. Hence they can now also utilize videoconferences and written decision-making. See also details on their website. Their decision is still due until the Ministry of Health decides on the resolution.

So, the market access route for drugs, medical devices, diagnostics, vaccinations is still open and ready for (new) innovations.

MArS has vast experience in market access strategy, the writing of applications and related price negotiations. Contact us!

Work environment given the COVID-19 outbreak

Dear clients, network partners, friends!!

Most of companies are moving now into home-office-based business given the outbreak of the COVID-19 virus! Home-office sounds easy, it is not always, especially if you have not (yet) a grown culture on that kind of work.

We at MArS always work from our home-offices, and we have specific tricks and recommendations you need to follow in order to make it successful! On the work environment section of our website you can find already some suggestions.

But please take this as an offer: Contact me or any MArS member to get insights how home-office can be made a successful story given the difficult situation we are currently all in.

Take care and stay at home!!

New analysis on external reference pricing shows negative impact on drug availability

Kanavos et al. just published another analysis on external reference pricing (ERP). ERP is widely applied by many payers across the world and also delivers short term cost savings for health care systems. Conclusions by Kanavos et al. are as follows: “ERP has not regulated prices efficiently and has unintended consequences that reduce the benefits arising from it. If ERP is carefully designed with minimal price revisions, prudent selection of basket size and countries, and consideration of transaction prices, it could be a more effective mechanism enhancing welfare, equitable access to medicines within countries and help promote industry innovation.”

The full article is available in the European Journal of Health Economics.

MArS has experience in pricing research and strategy as well as in price negotiations and can hence assess the ERP impact on the D-A-CH countries in detail.